Home › Compare › PHIOW vs HDV

PHIOW vs HDV: Dividend Comparison 2026

PHIOW yields 8620.69% · HDV yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHIOW wins by $12793007580007856.00M in total portfolio value
10 years
PHIOW
PHIOW
● Live price
8620.69%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12793007580007856.00M
Annual income
$12,507,597,271,400,990,000,000.00
Full PHIOW calculator →
HDV
iShares Core High Dividend ETF
● Live price
2.92%
Share price
$135.39
Annual div
$3.96
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$352.73
Full HDV calculator →

Portfolio growth — PHIOW vs HDV

📍 PHIOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHIOWHDV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHIOW + HDV cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PHIOW pays
HDV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHIOW
Annual income on $10K today (after 15% tax)
$732,758.62/yr
After 10yr DRIP, annual income (after tax)
$10,631,457,680,690,841,000,000.00/yr
HDV
Annual income on $10K today (after 15% tax)
$248.52/yr
After 10yr DRIP, annual income (after tax)
$299.82/yr
At 15% tax rate, PHIOW beats the other by $10,631,457,680,690,841,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHIOW + HDV for your $10,000?

PHIOW: 50%HDV: 50%
100% HDV50/50100% PHIOW
Portfolio after 10yr
$6396503790003928.00M
Annual income
$6,253,798,635,700,495,000,000.00/yr
Blended yield
97.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PHIOW right now

PHIOW
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-9.1
Piotroski
2/9
HDV
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHIOW buys
0
HDV buys
0
No recent congressional trades found for PHIOW or HDV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHIOWHDV
Forward yield8620.69% ✓2.92%
Annual dividend / share$2.00$3.96 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$12793007580007856.00M ✓$24.3K
Annual income after 10y$12,507,597,271,400,990,000,000.00 ✓$352.73
Total dividends collected$12773964733154094.00M ✓$3.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PHIOW vs HDV ($10,000, DRIP)

YearPHIOW PortfolioPHIOW Income/yrHDV PortfolioHDV Income/yrGap
1← crossover$872,769$862,068.97$11,002$292.38+$861.8K → PHIOW
2$71,250,409$70,316,545.72$12,084$300.36+$71.24M → PHIOW
3$5,441,140,196$5,364,902,258.92$13,250$308.02+$5441.13M → PHIOW
4$388,717,812,241$382,895,792,231.73$14,506$315.35+$388717.80M → PHIOW
5$25,980,665,800,186$25,564,737,741,087.56$15,858$322.35+$25980665.78M → PHIOW
6$1,624,683,420,105,904$1,596,884,107,699,705.00$17,313$329.04+$1624683420.09M → PHIOW
7$95,065,580,496,684,460$93,327,169,237,171,150.00$18,878$335.42+$95065580496.67M → PHIOW
8$5,205,346,525,995,166,000$5,103,626,354,863,713,000.00$20,560$341.49+$5205346525995.15M → PHIOW
9$266,738,606,174,640,700,000$261,168,885,391,825,900,000.00$22,367$347.25+$266738606174640.66M → PHIOW
10$12,793,007,580,007,855,000,000$12,507,597,271,400,990,000,000.00$24,307$352.73+$12793007580007856.00M → PHIOW

PHIOW vs HDV: Complete Analysis 2026

PHIOW — Stock

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Full PHIOW Calculator →

HDV — ETF

The iShares Core High Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.

Full HDV Calculator →
📬

Get this PHIOW vs HDV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHIOW vs SCHDPHIOW vs JEPIPHIOW vs OPHIOW vs KOPHIOW vs MAINPHIOW vs VYMPHIOW vs DVYPHIOW vs SPHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.